Metabolix Announces Commencement of Public Offering of Common Stock
Metabolix, Inc. (NASDAQ: MBLX), a bioscience company focused on
developing sustainable solutions for plastics, chemicals and energy,
today announced that it has commenced a public offering of shares of its
common stock pursuant to the Company’s effective shelf registration
statement filed with the U.S. Securities and Exchange Commission (the
“SEC”). Jefferies & Company and Thomas Weisel Partners LLC will serve as
the underwriters for this offering. The underwriters also have the
option to purchase up to an additional 15 percent of the offered amount
of common stock from the Company at the public offering price, less
underwriting discounts and commissions, within 30 days, to cover
over-allotments, if any. The offering is subject to market conditions,
and there can be no assurance as to whether or when the offering may be
completed, or as to the actual size or terms of the offering. The
Company intends to use the net proceeds it receives from the offering
for working capital and other general corporate purposes.
The shares will be issued pursuant to an effective shelf registration
statement that was previously filed with the SEC and was declared
effective on January 30, 2008. A preliminary prospectus supplement
related to the offering has been filed with the SEC and is available on
the SEC’s website http://www.sec.gov.
Copies of the prospectus supplement relating to these securities may be
obtained from Jefferies & Company, Inc., 520 Madison Avenue, New York,
NY 10022, 1-888-449-2342 or Thomas Weisel Partners LLC, One Montgomery
Street, San Francisco, CA 94104, 1-415-364-2720.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About Metabolix
Founded in 1992, Metabolix, Inc. is an innovation-driven bioscience
company focused on providing sustainable solutions for the world’s needs
for plastics, chemicals and energy. The Company is taking a systems
approach, from gene to end product, integrating sophisticated
biotechnology with advanced industrial practice. Metabolix is now
developing and commercializing Mirel™, a family of high performance
bioplastics which are biobased and biodegradable alternatives to many
petroleum-based plastics. Metabolix is also developing a proprietary
platform technology for co-producing plastics, chemicals and energy,
from crops such as switchgrass, oilseeds and sugarcane.
For more information, please visit www.metabolix.com.
(MBLX-E)
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made
pursuant to the safe harbor provisions of Section 27A of the Securities
Act of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended. The forward-looking statements in this press
release do not constitute guarantees of future performance. Investors
are cautioned that statements in this press release which are not
strictly historical statements, including, without limitation,
statements regarding expectations for Metabolix research and development
programs, constitute forward-looking statements. Such forward-looking
statements are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those anticipated and are
detailed in Metabolix’s filings with the Securities and Exchange
Commission, including its annual report on Form 10-K and quarterly
reports on Form 10-Q. Metabolix assumes no obligation to update any
forward-looking information contained in this press release or with
respect to the announcements described herein.
